Qiagen N.V. (QGEN) Stake Lowered by Flossbach Von Storch AG

Flossbach Von Storch AG decreased its stake in Qiagen N.V. (NASDAQ:QGEN) by 23.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 114,175 shares of the company’s stock after selling 35,825 shares during the period. Flossbach Von Storch AG owned approximately 0.05% of Qiagen N.V. worth $3,800,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of QGEN. Wetherby Asset Management Inc. raised its position in shares of Qiagen N.V. by 1.8% in the first quarter. Wetherby Asset Management Inc. now owns 9,273 shares of the company’s stock valued at $269,000 after buying an additional 163 shares during the period. Public Employees Retirement Association of Colorado raised its stake in Qiagen N.V. by 3.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock valued at $242,000 after buying an additional 246 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Qiagen N.V. by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 73,215 shares of the company’s stock valued at $2,121,000 after buying an additional 306 shares during the last quarter. Capstone Asset Management Co. raised its stake in Qiagen N.V. by 1.2% in the second quarter. Capstone Asset Management Co. now owns 75,003 shares of the company’s stock valued at $2,515,000 after buying an additional 873 shares during the last quarter. Finally, Parametrica Management Ltd raised its stake in Qiagen N.V. by 38.7% in the first quarter. Parametrica Management Ltd now owns 10,107 shares of the company’s stock valued at $293,000 after buying an additional 2,818 shares during the last quarter. 60.07% of the stock is owned by hedge funds and other institutional investors.

Shares of Qiagen N.V. (QGEN) traded down 0.60% during mid-day trading on Friday, reaching $31.25. 469,055 shares of the company traded hands. Qiagen N.V. has a 52-week low of $24.89 and a 52-week high of $35.26. The stock’s 50 day moving average is $32.99 and its 200 day moving average is $31.27. The stock has a market capitalization of $7.13 billion, a PE ratio of 95.57 and a beta of 1.14.

Qiagen N.V. (NASDAQ:QGEN) last released its earnings results on Thursday, July 27th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The firm had revenue of $349 million for the quarter, compared to analysts’ expectations of $353.09 million. During the same quarter in the previous year, the business posted $0.24 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, analysts anticipate that Qiagen N.V. will post $1.22 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by BNB Daily and is the property of of BNB Daily. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/qiagen-n-v-qgen-shares-sold-by-flossbach-von-storch-ag-updated-updated.html.

Several equities research analysts have recently issued reports on QGEN shares. TheStreet raised shares of Qiagen N.V. from a “c” rating to a “b” rating in a research report on Monday, June 5th. Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen N.V. in a report on Tuesday, June 6th. Barclays PLC reaffirmed a “buy” rating and set a $33.00 price target on shares of Qiagen N.V. in a report on Monday, May 15th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen N.V. in a report on Tuesday, May 2nd. Finally, BidaskClub lowered shares of Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 10th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $33.17.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Institutional Ownership by Quarter for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply